Cytodyn Inc (CYDY)

[BlackDoggie]

I disagree that it's mostly sentiment, it's economic rationality. If I'd been in on the Paulson raises all along and could (recently) buy shares at $0.50, sell them at $0.53, and keep the warrants, that's what I'd be doing too. The risk/reward of keeping massive chunks of money in an illiquid, OTC stock just doesn't make sense if you can keep the warrants, even if you're a very wealthy investor. Calling it "sentiment" is misguided when you examine the reality of where the supply of shares on the market is coming from.

I think that your link to the listing standards is broken - didn't work for me anyways - but you're going to need to refer to the initial listing standards. They differ from the ongoing listing requirements. This was the subject of a long and thorough discussion on the board back in March/April of last year.

https://www.nyse.com/publicdocs/nyse/listing/NYSE_Initial_Listing_Standards_Summary.pdf

NASDAQ has similar initial listing requirements:

https://listingcenter.nasdaq.com/assets/initialguide.pdf

Regarding selling ex-US rights, that sounds great, but I don't know how that's going to work out. I have a lingering question that research and repeatedly asking the board has not answered: how does licensing or sale of rights to leronlimab work for a single indication, when the exact same compound and delivery mechanism is expected to be effective in multiple - and large - indications. How do you sell the rights to distribute Advil for use for a fever, but not for a headache? It's obviously a little more nuanced for prescription drugs, but it's not like prescription drugs are never used off label. I've long thought that this is why we don't have a partner or buyer for HIV or GvHD individually, and now cancer is in the picture as well. But then, regardless of my personal ignorance, most BP would have known the history of the preclinical work and the links between CCR5 HIV mechanisms and cancer metastasis, so cancer likely would have been part of the thinking for them all along.